Home > Boards > US Listed > Biotechs > Chimerix, Inc. (CMRX)

Chimerix to Address Congressional Subcommittee in Support of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H8ster Member Profile
 
Followed By 82
Posts 5,933
Boards Moderated 1
Alias Born 01/23/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 4:07:28 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 9/30/2020 9:57:20 AM
Chimerix to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 9/10/2020 8:00:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/21/2020 4:31:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/19/2020 5:35:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/11/2020 5:50:45 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/11/2020 8:20:53 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/10/2020 5:54:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:39:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:18:40 AM
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2020 12:55:52 PM
Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020 GlobeNewswire Inc. - 8/3/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 1:02:59 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/23/2020 1:00:23 PM
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer GlobeNewswire Inc. - 6/22/2020 7:00:10 AM
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series GlobeNewswire Inc. - 6/18/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2020 1:18:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:49:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:45:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:44:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:43:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:41:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:41:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:39:27 PM
H8ster   Friday, 06/08/18 05:40:51 PM
Re: None
Post # of 625 
Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

Address Congressional Subcommittee

DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C.

The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.

“Unfortunately, the threat of a biological event impacting the United States has never been more real,” said Dr. Berrey. “Our private-public partnerships over the last 15 years, particularly with BARDA, have been critical to the survival and progression of our smallpox program with brincidofovir. We commend the Committee for bipartisan collaboration on the PAHPA reauthorization. Companies like ours rely on the existence of a government market for medical countermeasures to sustain the long-term investment of researching and developing these therapies, which provide a critical bulwark against biological threats.”……………...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences